Genetic testing is transforming pain management, according to a new study led by Julie Johnson, Pharm.D., and Noor Nahid, Ph.D., at The Ohio State University. By focusing on the CYP2D6 enzyme, researchers uncovered why some patients struggle to find relief from commonly prescribed opioids and how screening for genetic differences and drug interactions could help physicians tailor pain treatment for better outcomes. The study found that patients with reduced CYP2D6 activity are more likely to experience poor pain control and require additional visits to the emergency department.
With chronic pain affecting millions and driving up healthcare costs, this research highlights the promise of pharmacogenetic testing to reduce emergency department visits and improve patient care. Personalized medicine is advancing pain relief, and understanding your genetics could be the key to more effective treatment.
Read the full article here.
